Vestura Discontinuation: What Providers and Prescribers Need to Know in 2026

The discontinuation of Vestura (drospirenone 3 mg / ethinyl estradiol 0.02 mg) by Teva Pharmaceuticals has led to a wave of patient inquiries across OB-GYN, family medicine, and telehealth practices. This clinical guide summarizes what prescribers need to know to manage the transition smoothly for their patients.

Clinical Background: What Was Vestura?

Vestura was an FDA-approved branded generic of Yaz, containing drospirenone 3 mg (a fourth-generation progestin with antimineralocorticoid and antiandrogenic properties) and ethinyl estradiol 0.02 mg. It was dispensed as a 28-day monophasic pack with a 24/4 schedule (24 active + 4 inert tablets).

FDA-approved indications included:

• Contraception
• Premenstrual dysphoric disorder (PMDD)
• Moderate acne vulgaris (females ≥14 years old who desire oral contraception)

Nature of the Discontinuation

Teva's decision to discontinue Vestura was a commercial/manufacturing decision, not a safety withdrawal. There are no outstanding FDA safety alerts, Class I/II/III recalls, or post-market safety signals specific to the Vestura formulation that prompted the discontinuation. Providers should reassure patients accordingly.

FDA-Approved Therapeutic Equivalents (AB-Rated)

All of the following contain drospirenone 3 mg / ethinyl estradiol 0.02 mg in a 24/4 monophasic regimen and are FDA AB-rated equivalents to Yaz (and thus to Vestura):

• Nikki — pharmacologically closest to Vestura's inactive ingredient profile; recommended first transition option for patients who tolerate drospirenone well
• Loryna — widely stocked; good first-line substitute when patient is transitioning from Vestura
• Gianvi — commonly dispensed as a substitute by pharmacists; AB-rated equivalent
• Syeda, Jasmiel, Lo-Zumandimine, Zumandimine — additional AB-rated options; availability varies by region
• Yaz (brand) — original reference listed drug; identical formulation, higher cost, may be appropriate for patients who tolerate generics poorly

Prescribing Considerations When Transitioning Patients

When updating prescriptions for patients currently on Vestura:

1. Specify a preferred generic by name (e.g., Nikki or Loryna) rather than writing the drug name only, to ensure pharmacists dispense your preferred formulation when multiple are in stock.
2. Counsel patients on the transition — explain that the active hormones are identical but inactive ingredients may differ. Minor symptoms (minor spotting, mild nausea) are common in the first 1-2 months.
3. Consider a 90-day supply once a toleratable generic is identified, to reduce the likelihood of future stocking disruptions.
4. Monitor potassium levels in patients on concomitant medications that elevate potassium (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs) — this requirement applies to all drospirenone-containing COCs.

Patients Who Are Sensitive to Generic Switches

A subset of patients reports clinical differences when switched between generics, likely attributable to inactive ingredient variation. For these patients:

• Recommend Nikki as the first alternative (most similar inactive ingredient profile to Vestura)
• If inactive ingredient sensitivity is a documented concern, consider prescribing brand-name Yaz (dispense as written)
• Document the clinical rationale for brand-name dispensing in the chart if prior authorization is required

Supporting Patients Who Can't Find Stock

If patients report difficulty finding drospirenone/EE generics in stock, direct them to medfinder for providers — a service that calls pharmacies on patients' behalf to locate in-stock medications and texts patients results.

VTE Risk Reminder

All drospirenone-containing COCs (including the equivalents above) carry a class warning regarding potentially higher VTE risk compared to COCs containing levonorgestrel or other progestins. The FDA prescribing information notes that epidemiologic studies have found a VTE risk ranging from no increase to approximately three-fold increase versus levonorgestrel-containing COCs. This risk-benefit discussion is unchanged regardless of which drospirenone generic is prescribed.

Resources for Your Practice

For a step-by-step guide on helping your patients locate available stock, see How to Help Your Patients Find Vestura in Stock: A Provider's Guide.